Targeting hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel and preparation method thereof
A technology of supramolecular hydrogel and hyaluronic acid, which is applied in the direction of pharmaceutical formulations, organic active ingredients, and non-effective ingredients of polymer compounds, etc., can solve the problems of low loading rate of doxorubicin, large toxic and side effects of doxorubicin, etc. Achieve the effects of enhancing tissue permeability and drug efficacy, improving targeting performance, and stabilizing the drug-loading system
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0049] A targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel, prepared from α-CD, F127, HA-β-CD and doxorubicin (DOX), which is non-covalently embedded in the hydrogel network.
[0050] The synthetic steps of the HA-β-CD used are:
[0051] The intermediate HA-β-CD is further synthesized by reacting the hyaluronic acid derivative HA-ADH with the p-toluenesulfonyl-modified cyclodextrin derivative 6-OTs-β-CD, and the specific steps are as follows:
[0052] Dissolve 0.5g of hyaluronic acid derivative HA-ADH and 1g of cyclodextrin derivative 6-OTs-β-CD in 100mL of phosphate buffer solution with pH=7.4, after they are dissolved, add 10g of N-methylpyrrolidone (NMP), it was placed under the condition of 80° C. for 24 hours. After stopping the reaction, put it into a dialysis bag, dialyze with a large amount of deionized water for 72 hours, and then freeze-dry to obtain a white powder HA-β-CD. Its chemical structure is characterized by 1H NMR, D 2 O as a solve...
Embodiment 2
[0061] The HA-β-CD used in this example is the HA-β-CD prepared in Example 1.
[0062] A targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel, prepared from α-CD, F127, HA-β-CD and DOX, and doxorubicin embedded in the hydrogel in a non-covalent way glue network. The preparation method of the targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel is as follows:
[0063] Take 0.4g of HA-β-CD and 0.2g of F127 in the reactor, add 3mL of deionized water, and stir at 60°C for 4h. Then 0.4g of α-CD was added to the system, and the stirring was continued at 60°C for 4 hours. The whole process was carried out in the dark, and then 0.16g of DOX was added to the hydrogel, and the stirring was continued for 2 hours. After the stirring, the system was slowly cooled to room temperature, left to stand for 12 hours, and then freeze-dried for 12 hours to obtain a dry targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel.
Embodiment 3
[0065] The HA-β-CD used in this example is the HA-β-CD prepared in Example 1.
[0066] A targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel, prepared from α-CD, F127, HA-β-CD and DOX, and doxorubicin embedded in the hydrogel in a non-covalent way glue network. The preparation method of the targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel is as follows:
[0067] Take 0.2g of HA-β-CD and 0.2g of F127 in the reactor, add 3mL of deionized water, and stir at 60°C for 4h. Then 0.6g of α-CD was added to the system, and the stirring was continued at 60°C for 4 hours. The whole process was carried out in the dark, and then 0.16g of DOX was added to the hydrogel, and the stirring was continued for 2 hours. After the stirring, the system was slowly cooled to room temperature, left to stand for 12 hours, and then freeze-dried for 12 hours to obtain a dry targeted hyaluronic acid-cyclodextrin drug-loaded supramolecular hydrogel.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More